The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades. Unlike existing medications that ...
Dual art therapy, combining music and painting, significantly improved symptoms, cognitive function, and quality of life in ...
As treatment for schizophrenia changes, LAIs are becoming increasingly important as maintenance therapy. Teva's pursuit of an ...
How Does Cobenfy Work, and How Is It Different From Other Medicines Used to Treat Schizophrenia? An imbalance of brain chemicals called neurotransmitters may contribute to schizophrenia. Current ...
No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...
The general consensus among experts is that TRS is a condition in which an individual’s symptoms haven’t responded to two or more antipsychotic medicines given at a therapeutic dose for at least six ...
On December 11, 1951, in the labs of French pharmaceutical company Rhône-Poulenc, chemist Paul Charpentier concocted a drug that would change the field of psychiatry forever. Charpentier hadn’t ...
Panelists discuss how CT-155, a 16-week interactive digital application, met its primary end point in clinical trials by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback